In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sybron Quietly Builds a Powerhouse

Executive Summary

Sybron International, hardly a well-known name in the diagnostics industry, has built a $350 million highly profitable diagnostics business by acquiring small, niche companies. Its latest acquisition, Microgenics Corp., makes it an important player in the drugs of abuse and therapeutic drug monitoring businesses. Microgenics had been part of Boehringer Mannheim Corp. But when Roche bought Boehringer Mannheim, the FTC required Roche to sell off Microgenics for anti-trust reasons. Microgenics was sold last summer to an investor group, which sold it to Sybron.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts